PGAM1 is often upregulated in various cancers, including breast, lung, and prostate cancers, contributing to tumor growth and progression by coordinating glycolysis and anabolic processes which makes it an appealing target for drug development. This evidence concerns the gene PGAM1 and Familial prostate cancer.